FOSUN PHARMA

Investor Presentation

May 2021

Prepared in accordance with China Accounting Standards

Disclaimer

This document has been prepared by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the “Company”) and is for presentation use only. Copying, reproduction or redistribution of this document to any person is strictly prohibited. The information contained in this document has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The purpose of this document is not for a complete or full analysis of any financial or trading position or prospect, and any person who will be in possession of this document shall be aware that no reliance should be placed on any content contained herein. The information and opinions contained in this document are subject to change without notice, nor will the document be updated to reflect any developments which may occur after the date of this document. The Company or any of its affiliates, advisors or representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

This document contains forward-looking statements that are subject to assumptions, risks and uncertainties. These forward-looking statements are generally expressed in forward-looking expressions, such as expectations, estimation, planning, projections, goals, possibilities, probabilities or so on to reflect the actions that the Company expect to or may take in the future or the results from these actions. You should not place undue reliance on these forward-looking statements. Actual results may differ from these forward-looking statements.

This document is for review only by persaons who are (i) a ''qualified institutional buyer'' ("QIB") as defined under Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act") in the United States; or (ii) outside the United States as defined under Regulation S under the Securities Act. By your acceptance of this presentation, you acknowledge that you satisfy the requirements and conditions set forth in the preceding sentence. The distribution of this document in any jurisdiction may be restricted by laws, and persons into whose possession it comes must inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the federal securities laws of the United States and the laws of other jurisdictions.

This document is not intended to constitute an offer to, or a solicitation for offer to, sell, purchase or subscribe for any securities nor shall it or any part of it form the basis of or being relied on for any contracts or promises.

NO SECURITIES OF THE COMPANY MAY BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OF THE UNITED STATES. THE SECURITIES TO BE OFFERED BY THE COMPANY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR ANY STATE SECURITIES LAWS OF THE UNITED STATES. THIS PRESENTATION MATERIAL DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF THE SECURITIES ACT.

FOSUN PHARMA
Innovation for Good Health

Contents



FOSUN PHARMA
Innovation for Good Health

Financial Results Overview

Key Financials (RMB million)	2019	2020	YoY (%)	1Q20	1Q21	YoY (%)
Revenue	28,585	30,307	*6.02*	*5,881*	*8,056*	*37.00*
Net profit attributable to shareholders	3,322	3,663	*10.27*	*577*	*847*	*46.78*
Net profit after one-off gain	2,234	2,718	*21.65*	*436*	*658*	*50.76*
Net operating cash flow	3,222	2,580	*-19.94**	*382*	*737*	*92.62**
Basic EPS (Rmb/share)	1.30	1.43	*10.00*	*0.23*	*0.33*	*43.48*
Payout Ratio (To be approved at the AGM)	30%	30%	-	-	-	-

Note : In 2020, operating cash flow increased 11.19% YoY after deducting the impact of the Euro 125mn upfront payment to BioNTech for the mRNA COVID-19 vaccine.
In 1Q21, the YoY increase in operating cash flow was mainly due to 1) revenue and profit increased YoY caused the corresponding operating cash flow to increase; 2) receiving of the first payment for mRNA vaccine from governments of Hong Kong and Macao and the contribution after paying relevant expenses from procurement, R&D and selling.





FOSUN PHARMA
Innovation for Good Health

Results Overview

Revenue



Operating Cash Flow



Profit Attributable



Net profit after One-off Gain



Note: Operating cash flow shown above excluded the impact of the EUR125 mn upfront payment to BioNTech for the mRNA vaccine for covid-19; the R&D and sales preparation expenses for mRNA vaccine products were included in 2020 Q4.

FOSUN PHARMA
Innovation for Good Health

Operating Performance Analysis

Expense Structure	2019	2020	1Q20	1Q21
Gross Margin	*59.6%*	*55.7%*	*55.1%*	*52.5%*
Selling and Distribution	*34.4%*	*27.9%*	*28.6%*	*26.6%*
Administrative	*9.1%*	*9.8%*	*10.0%*	*8.4%*
R&D	*7.1%*	*9.2%*	*8.4%*	*8.0%*
Finance	*3.0%*	*2.4%*	*2.3%*	*1.6%*

Note: In 2020, the decrease of selling expense ratio was mainly due to: 1) structure change in sales revenue; 2) offline events are replaced by online events, causing the deduction of travel expense; 3) cost control over the sales activities; 4) selling expense decrease for GPO products.
In 2020, the decrease in gross margin was mainly due to 1) the structure change in sales revenue from the pharmaceutical segment; the sales volume of anti-infection and CNS injection products decreased – unit fixed cost increased ; 2) number of hospital visits decreased while the fixed cost takes a higher proportion in the operating costs – unit fixed cost increased.



Operating Results Margins	2019	2020
Total Results Margin	*9.9%*	*11.6%*
Pharmaceutical	*8.8%*	*10.3%*
Med Tech	*15.4%*	*20.2%*
Hospitals	*10.8%*	*6.2%*

FOSUN PHARMA
Innovation for Good Health

Liquidity and Capital Structure

Current Ratio



Quick Ratio



Debt Ratio



Equity attributable to owners of Parent



FOSUN PHARMA
Innovation for Good Health

Contents



FOSUN PHARMA
Innovation for Good Health

Pharma Segment Performance

Segment Revenue

(RMB million)



R&D

- Through in-house R&D, co-development, in-license and incubation, focus on oncology immunology, four hypes (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, central nervous system and other major therapeutic areas.
- Build small molecule innovative drugs, antibody drugs, cell therapy platforms, and actively explore cutting-edge technology fields such as RNA, oncolytic viruses and gene therapy.

Segment Results

(RMB million)



Manufacture

- Domestic: Build comprehensive formulation manufacturing center, enhance specialty formulation manufacturing base, continue to expand production capacity of biological
- Overseas: Set Gland Pharma as front station to enhance manufacture system with international standard

Segment Profit

(RMB million)



Commercialization

- With the launch of innovative products, established the innovative drug commercialization team, the new retail team, the professional sales & marketing team in Africa, Europe and the US. A comprehensive support team is also constructed for medical affairs, market access and brand promotion purposes.
- Continuously enhance the construction and integration of the commercialization system, adhering to the guidance of professional, brand and digital development.

FOSUN PHARMA
Innovation for Good Health

Commercialization– Core Therapeutic areas

Revenue of Core products



(RMB million)



FOSUN PHARMA
Innovation for Good Health

Commercialization - Newly Launched Blockbusters

Su Ke Xin®
Avatrombopag Maleate Tablets

- Approved for the treatment of CLDT. It is the world's **first oral drug** approved for this indication at present and also the first small molecule innovative drug of Fosun Pharma approved for launch;
- Launched in August 2020, it has covered **4,000** hospitals and DTP pharmacies in **31** provinces, districts and cities across the country, and recorded sales of Rmb**140mn** for 2020;
- Included in the **NRDL** in Dec 2020 which will come effective in Mar 2021 in 30 provinces;
- The Phase III clinical trial for the treatment of **ITP** has been approved by the NMPA.

Han Li Kang®
Rituximab Injection

- The **first biosimilar product approved for launch in China** in Feb 2019.
- Sales revenue reached **Rmb750mn** for the year and **more than 50%** of new patients used our products;
- **Production capacity improved** with the approval for the use of the 2,000L bioreactor and the extra specification of "500mg/50ml/bottle".
- Received approval in July for the treatment of **initially-treated FL and previously-untreated or r/r CLL**; in Nov phase III clinical trial for the treatment of **moderate to severe active RA** met the primary clinical endpoint.

Han Qu You®
Trastuzumab Injection

- Received approvals from EC and NMPA and became the **first mAb biosimilar approved in China and Europe**;
- Been prescribed within **6 working days** after approved in China. By Mar 19 medical insurance access in all provinces and cities were enabled with bidding and listing **in 28 provinces and cities** completed.
- Zercepac® was **successfully launched in nearly 20 EU countries and regions** including Germany, Spain, France, Ireland, Italy and Hungary, and been included in UK NHS and multiple world-leading hospitals.
- Recorded sales of **Rmb140mn** for 2020.

D-ARTEPP®
Dihydroartemisinin-Piperaquine Phosphate (Tablets / Dispersible Tablets) Anti-malarial Series

- Dihydroartemisinin Piperaquine Phosphate Tablets and Dispersible Tablets (D-Artepp Dispersible), a global pioneer of its kind, passed WHO PQ in 2020. So far all 21 products (and specifications) of the company obtained WHO PQ, and were registered and marketed in 38 major malaria-prone countries worldwide.
- Among them, Artesun (Artesunate for injection) was the **first choice** for the treatment of severe malaria recommended by the WHO, and was included in the national medication guidelines by countries with high malaria incidence, as the gold standard for the treatment of severe malaria.
- Supplied for nearly 10 million patients in 2020.

FOSUN PHARMA
Innovation for Good Health

Commercialization - 39 Products with sales over Rmb100mn

Over Rmb1bn

2 products

Rmb500mn to Rmb1bn

5 products

Rmb300mn to Rmb500mn

9 products

Rmb100mn to Rmb300mn

23 products



...

FOSUN PHARMA
Innovation for Good Health

Commercialization - Commercialization System



FOSUN PHARMA
Innovation for Good Health

R&D – Open R&D Ecosystem



- Established **Global R&D Centre** in early 2020 as an upgrade of internal R&D system, for overall pipeline management to enhance the efficiency of clinical study.
- Approximately **2,300** R&D staff – **7** % of the total number of Employees
- Strong R&D capabilities in China, U.S., and India with **247** ongoing pipeline projects





FOSUN PHARMA
Innovation for Good Health

R&D – Diversified R&D System

- **With diversified R&D System, accelerating R&D transformation, driving the development and commercialization of innovative products.**

- Rituximab Injection
- Trastuzumab for Injection
- Adalimumab Injection
- SAF189
- FCN-338
- Orin1001



- Avatrombopag
- Opicapone
- Tenapanore
- DaxibotulinumtoxinA for Injection
- SurVaxM
- Balixafortide

- T-Cell Therapy
- Stem Cell Therapy
- mRNA Vaccine （COVID-19）

- Early stage diagnosis of Lung Cancer
- Gene Therapy
- Lipolytic Solution （RZL012）
- Fosun Health （Suzhou） Fund， L.P.
  Fosun Health （Tianjin） Fund， L.P.
- Berkeley Catalyst Fund I, LP

FOSUN PHARMA
Innovation for Good Health

R&D – License in & Out

License-in

Successful global BD track record:

- Extensive global network through years of experience with operation of overseas subsidiaries, FOFs and collaboration with international partners;
- Over 20 years of operation experience in domestic healthcare market to increase value for our global partners

2018
- Avatrombopag from Dova
- Opicapone from Bial

2019
- Regenerative medicine: Stem cell therapy from ReNeuron

2020
- Avatrombopag approved for launch in China
- Opicapone exempted for Phase III clinical trial
- mRNA vaccine from BioNTech

License-out

Innovative Small Molecule Drug

- Fochon grant Lilly to develop, manufacture and commercialize BCL-2 inhibitor FCN-338 in regions except the greater China on 29th Oct 2020; Lily shall pay no exceeding **USD440 million** (including upfront payment of **USD40 million**, no exceeding **USD340 million** in development milestones and USD60 million in sales milestones.

Antibody-based Drug

- Grant Accord to exclusive commercialize HLX02 in Europe, the US and Canada with upfront payment of **USD35 million** and no exceeding **USD85 million** in development and sales milestones.
- Grant KG Bion to exclusive commercialize HLX10 in Southeast Asia with upfront payment of **USD10 million** and no exceeding **USD672 million** in development and sales milestones.
- Grant KG Bio to exclusive register, manufacture and commercialize the wet age-related macular degeneration and other eye disease related indication of HLX04 in the world with no exceeding **USD25 million** in upfront payment and development milestones.

Actively searching for collaboration opportunities with globally leading pharma player to unlock and maximize the commercial value of R&D outcomes.

FOSUN PHARMA
Innovation for Good Health

R&D - mRNA Vaccine Progress

Latest Progress

- Pfizer/BioNTech initiated the application for full approval of COVID-19 Vaccine for individuals aged 16 and older by submitting a **Biologics License Application (BLA)** on 7th May 2021 to the FDA, and the FDA authorized the emergency use of the Pfizer/BioNTech COVID-19 Vaccine for **12-15 age group adolescents** on 10th May 2021.
- Nature Medicine published the result of the Phase 1 clinical trial of the vaccine candidate BNT162b1, which is a vaccine candidate based on the RNA vaccine platform. The safety, tolerability and immunogenicity data from the study show the vaccine **has an acceptable safety profile and produces high levels of humoral and T cell responses in a Chinese population**.
- Fosun Pharma and BioNTech announced the mRNA COVID-19 vaccine has received **Emergency Use Authorization from the Food and Health Bureau of Hong Kong** on 26th Jan 2021. The vaccine also **received the Special Import Authorization from the Health Bureau of Macau** on 23rd Feb 2021. The injection of vaccine is actively taken place as planned.
- Fosun Pharma and BioNTech entered into an agreement in relation to the supply and manufacture of COVID-19 Vaccine on 15th Dec 2020. BioNTech commits to supply no less than **100 mn doses** of the COVID-19 Vaccine Product for Mainland China in 2021. The upfront payment for the initial supply of **50 mn doses** of the COVID-19 Vaccine is **EUR250 mn**. The upfront payment of **EUR125 mn** has been payed at the end of 2020.
- Fosun Pharma and BioNTech announced that NMPA has approved the clinical trial in Mainland China for mRNA vaccine BNT162b2 on 13th Nov 2020; and this clinical trail has been conducted in Taizhou and Lianshui, Jiangsu Province, China on 24th Nov 2020.

Other Relevant Information

Storage requirements:

- The COVID-19 Vaccine from Pfizer/BioNTech is authorized to be transported and stored at **-25 to -15 ℃** for **2 weeks** by the FDA.
- According to the first quarter report from BioNTech, Pfizer/BioNTech has submitted data to the FDA and the EMA for the authorization to store the COVID-19 Vaccine at **2 to 8 ℃ for 4-weeks**, and initiated Phase III clinical trial to evaluate **lyophilized** and **a ready-to use formulation**. Data is expected in the third quarter 2021.

Manufacturing capacity:

- According to the first quarter report from BioNTech, the potential capacity is **up to 3 billion** doses by end of 2021; **more than 3 billion** doses in 2022.

Mutations of Virus

- Pfizer/BioNTech announced on 27th Jan 2021 in-vitro studies that COVID-19 vaccine elicits antibodies that neutralize **SARS-CoV-2 with key mutations present in U.K. and South African variants.**
- Pfizer/BioNTech published a research on 8th Mar 2021 in New England Journal of Medicine, demonstrating that BNT162b2 elicits antibodies that neutralize **SARS-CoV-2 with key mutations present in Brazil variant.**

Other Clinical Trails:

- According to the first quarter report from BioNTech, the data from the ongoing study in children from **6 months to 11 years** of age is expected **in the third quarter 2021**; the trial to evaluate **variant-specific version BNT162b2SA** in naive and vaccinated individuals as well as **third dose** of BNT162b2 at 6-12 months post dose 2 is ongoing.

FOSUN PHARMA
Innovation for Good Health

R&D - mRNA Vaccine Progress

Fosun Pharmaceutical Industrial and BioNTech entered into a Term Sheet in relation to the proposed setting up of a Joint Venture Company for manufacturing and commercialization of the COVID-19 Vaccine.

Fosun Pharmaceutical Industrial (FOSUN PHARMA 复星医药)

50% — Capital contribution in the aggregate amount of not more than USD100 mn in cash and/or in tangible or intangible assets (comprising plants and manufacturing facility)

BioNTech (BIONTECH)

50% — Contribution in intangible assets including licensing of the relevant manufacturing technology and know-how, at the value of not more than USD100 mn

Localized Manufacture and Commercialization Platform

Manufacturing Facility

- The **potential capacity** is **up to 1 billion doses** of COVID-19 Vaccine per annum;
- Fosun Pharmaceutical Industrial shall **reconstruct the plant in Jinshan, Shanghai** for vaccine manufacturing;
- The manufacturing facility is expected to get **tested in the third quarter 2021 for IQ, OQ and PQ**.

Technology Transfer

- Under the Term Sheet, BioNTech shall be responsible for **conducting technology licensing** through entering into a technology license agreement and **providing technology assistance**, and shall ensure **sufficient capable personnel** in connection therewith.

Commercialization

- The JV Company shall engage **the affiliate of Fosun Pharmaceutical Industrial** as the **Contract Sales Organization (CSO)** to provide **marketing and sales services;**
- **The commercialization team (more than 500 employees)** will target C (Customer), B (Business), G (Government), P (Third Platform) and HCP (Health Care Provider).

Future Collaboration

- Fosun Pharmaceutical Industrial and BioNTech may **potentially expand collaboration into other infectious diseases and therapeutic areas based on the mRNA platform**, subject to the success of the vaccine in China.
- The JV Company shall have a **right of first refusal** with respect to the **production of any mRNA-based therapy or vaccine** with certain agreed exceptions.

FOSUN PHARMA
Innovation for Good Health

Note: The definitive transaction documents are expected to be executed by middle of June 2021.

R&D - Incubation & Early-stage Investment



FOSUN PHARMA
Innovation for Good Health

R&D - In-house Development: Bio-Medicine Core Pipeline

	Product		Target	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Near Commer-Cialization	HLX01(Rituximab)		CD20	Rheumatoid Arthritis	
	HLX04(Bevacizumab)		VEGF	metastatic Colorectal Cancer / non-squamous Non-Small Cell Lung Cancer	
	HLX10 Mono		PD-1	Microsatellite Instability-high Solid Tumors（MSI-H）	
Clinical Stage	HLX10	Mono	PD-1	Chronic Hepatitis B	
		+chemo	PD-1	metastatic Esophageal Carcinoma	
				Squamous Non-Small Cell Lung Cancer	
				Extensive Small Cell lung Cancer	
				Gastric Cancer	
		+HLX04	PD-1+VEGF	Non-squamous Non-Small Cell Lung Cancer	
				Metastatic colorectal cancer	
				Hepatocellular Carcinoma	
		+HLX07	PD-1+EGFR	Squamous Cell Carcinoma of Head and Neck	
	HLX07		EGFR	Solid tumor	
	HLX05(Cetuximab)		EGFR	metastatic colorectal cancer (mCRC)/squamous cell carcinoma of the head and neck	
	HLX12(Ramucirumab)		VEGFR2	Gastric cancer/ metastatic non small cell lung cancer/Mcrc	
	HLX20		PD-L1	Solid tumor	
	HLX22		HER2	Breast cancer/Gastric cancer	
	HLX55		c-MET	Solid tumor	
	HLX11(Pertuzumab)		HER2	Breast cancer	
	HLX14(Denosumab)		RANKL	Osteoporosis	
	HLX04-o		VEGF	wet Age-related Macular Degeneration	
	HLX13(Ipilimumab)		CTLA-4	Melanoma/ Renal cell carcinoma, mCRC	

Note: Clinical trial progress updated to Apr 27, 2021.

FOSUN PHARMA
Innovation for Good Health

R&D – Innovative Small Molecule Core Pipeline

- **Fochon** granted **Lilly** exclusive rights to develop and commercialize FCN-338 in all countries and regions excluding Mainland China, Macao and Hong in Oct 2020. Lilly shall pay Fochon upfront payment of **USD40 million** and up to **USD400 million** in potential development and commercial milestones.

Therapeutic Area	Project	MOA	Indication	Pre-clinical / IND / Phase 1 / Phase 2 / Phase 3
Oncology	Furitinib succinate (FC-110/SAF-189)	ALK/ROS1	Late Stage NSCLC	Phase II approved in the US
	FCN-437	CDK4/6	Solid tumors	Phase I in the US
	FN-1501	FLT3	Leukemia	Phase I in the US and AU
	FCN-411	Pan-HER	mNSCLC/HSNCC	
	Orin1001	-	r/r and metastatic Breast Cancer and advanced solid tumor	Phase I in the US
	FCN-159	MEK	Malignant melanoma Neurofibromatosis type 1	
	FS-1502	HER2	Breast cancer	
	FCN-647	BTK	Lymphoma	
	FCN-011	pan-TRK	NTRK fusion-positive solid tumors	
	FCN-338	BCL-2	Hematologic Malignancy	Phase I approved in the US
Metabolism and Digestive System	Wanbang SGLT-2 inhibitor	SGLT-2	Type II Diabetes	
	FCN-207	URAT1	Hyperuricemia / Gout	
Other	Orin1001	-	Idiopathic pulmonary fibrosis	Phase I approved in the US

Note: Clinical trial progress updated to Apr 27, 2021.

FOSUN PHARMA
Innovation for Good Health

R&D – In-licensed Pharmaceutical Products

Therapeutic Area	Generic Name	Registration Category	Indication	Progress in China	Overseas Progress
Metabolism and Digestive System	Tenapanor Tablet	Chem 1	Irritable Bowel Syndrome with Constipation	Phase I	Launched in the US
	Ferric Pyrophosphate Citrate	Chem 5.1	Iron replacement for HD patients	Phase III	Launched in the US Triferic (solution)
Oncology	Balixafortide	Chem 1	Breast cancer	Phase III application preparing	Phase III Multi Regional Clinical Trial (MRCT) preparing
	SurvaxM injection	Chem 1	Severe Glioblastoma	Phase III application preparing	Phase III Multi Regional Clinical Trial (MRCT) preparing
Infectious Diseases	mRNA vaccine BNT162b2	Chem 1	COVID-19	Phase II	CMA, EUA or temporary authorization in more than 50 Countries
	PA-824	Chem 1.1	XDR – Tuberculosis MDR – Tuberculosis	Phase I	Launched in the US Pretomanid
Nervous System	Opicapone Capsule	Chem 5.1	Adult Parkinson's Patients	NDA accepted (Phase III exempted)	Launched in Europe Ongentys
Blood System	Avatrombopag Tablet	Chem 2.4	Idiopathic Thrombocytopenic Purpura	Phase III approved	Launched in the US, Europe
	Tenapanor片	Chem 1	End-stage Renal Disease – Hemodialysis	Phase III approved	Completed phase III
Others	RT002	Bio 1	Moderate-to-Severe Glabellar Lines	Phase III approved	Launched in the US
			Cervical Dystonia	Phase III approved	Phase III
	Fortacin spray (Lidocaine Prilocaine spray)	Chem 5.1	Premature ejaculation	Clinical trial application preparing	Launched in Europe
	Bremelanotide injection	Bio 1	Hypofunctional female sexual desire disorder	Phase I	Launched in the US

Note: Clinical trial progress updated to Apr 27, 2021.

FOSUN PHARMA
Innovation for Good Health

Manufacturing – International manufacturing System

Overseas: International GMP certification

International Standard

- 10 productions lines of domestic member enterprises obtained the GMP certification of US FDA, EU, MHLW Japan and MOH Germany;
- Gland Pharma's production lines obtained GMP certifications from US, EU, Japan, Australia and other countries/regions;
- Gland Pharma completed the construction of new lyophilization line and hormone product line in 2020, laying a foundation for further increase in production capacity in 2021.

Domestic capacity expansion and integration

Biopharmaceutical:

- Xuhui Facility: improved from 2,000L in 2019 to **20,000 L** and received EU GMP certificate
- Songjiang Facility: Plant (1) with planned capacity of **24,000 L** and trial production commenced in 2Q20; Plant (2) with planned capacity **36,000 L** and aim to commence trial production in 2021.

Small Molecule Drugs:

- Comprehensive formulation production sites such as Wanbang and Yao Pharma and Xingnuo API sites.
- Integrated specialty formulation production sites and constructed 3 API sites.

Map source: https://www.zrzyst.cn/, Figure number: GS (2016) 1549

FOSUN PHARMA
Innovation for Good Health

Contents

Financial Results

Pharmaceutical

Med Tech

Healthcare Service

Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Med Tech Segment Performance

Segment Revenue

(RMB million)



Segment Results

(RMB million)



Segment Profit

(RMB million)



Medical Devices

Aesthetic Field

- As the core medical aesthetic platform, sisram's business covers energy based medical aesthetic devices, professional dental devices and injectable, etc.

Respiratory Care

- Exploiting home/hospital used respiratory devices market through Breas

Professional Medical Device & consumables

- Including Da Vinci surgical robotic system, negative pressure ambulances and other professional medical device with lead position in their own field

Medical Diagnosis

Fosun Long March

- Fosun Long March's business covers molecular diagnosis, immuno diagnosis, biochemical diagnosis, microbiological diagnosis, POCT, glycomics and mass spectrum diagnosis

Yaneng Bio

- Yaneng Bio take the gene chip as core technology platform, which main products are HPV diagnostic reagent and thalassemia gene test reagent

Note: the acquisition of foshion is still need to be approved by Annual General Meeting.

FOSUN PHARMA
Innovation for Good Health

Medical Devices – Core Platforms

Medical Devices

Aesthetic Field

Sisram Medical is the leading provider of energy based surgical and medical aesthetic solutions and has comprehensive in-house capability with R&D, manufacturing, marketing and sales. Sisram focuses on the treatment of hair removal, skin rejuvenation, skin tightening, pigmented lesions, etc.
Sisram keeps integrating medical aesthetic businesses. The proposed acquisition is part of Sisram's objective to build a wellness ecosystem, acknowledging the dental devices and injectables as the next medical aesthetics frontier, and taking into consideration the significant growth projections for the industry and potential synergies with Sisram's existing businesses.




Respiratory Care

Breas is found in Gothenburg, Sweden, which covering R&D, manufacture and sales of professional respiratory medical device; Combine digital service to exploit home/hospital used respiratory devices market.


Professional Medical Device & Consumables

Chindex is exclusive agent for leading product, including imaging equipment, cancer treatment equipment, etc.

Intuitive is mainly responsible for R&D, manufacture, sales of products for the early stage diagnosis and treatment of lung cancer; began to sell Da Vinci surgical robotic system in 2019.

It is a specialized vehicle sales, focusing on imported ambulances and high-end modified ambulances.



Note: the acquisition of foshion is still need to be approved by Annual General Meeting.

FOSUN PHARMA
Innovation for Good Health

Medical Devices – Sisram Medical Ltd (1696.HK)

- Sisram Medical is the leading provider of energy based surgical and medical aesthetic solutions and has comprehensive in-house capability with R&D, manufacturing, marketing and sales. Sisram focuses on Medical Aesthetics, Surgical and Beauty, and owns flagship family systems such as Soprano for hair removal, Accent for skin tightening, Harmony for skin rejuvenation, etc.
- **Sisram Medical expands its dental business with proposed acquisition of 100% issued share capital of Foshion Dental with RMB 312.4mn in cash on 22nd April 2021. The proposed acquisition is part of Sisram's objective to build a wellness ecosystem.**
- Sisram recorded significant recovery in the second half of 2020. Revenue in 2H20 increased by 2.6% compared to 2H19 and increased by 26.0% compared to 1H20. Net profit increased by 10.8% compared to 2H19 and increased by 55.9% compared to 1H20.
- Based on an increase in the product demand and the backlog of orders as of 31st Dec 2020, barring any unforeseen circumstances or material change in market conditions, Sisram expects to record a significant growth in revenue of over 40% in 1H21 as compared to 1H20.



New Launches:

Sisram launched four new highly innovative products during 2020:

1) Opus Plasma, the first plasma skin resurfacing platform;
2) Mutli-functional platform Harmony XL PRO Special Edition with the new, groundbreaking hand piece, doubling the power of previous solutions for skin rejuvenation;
3) DermaClear, 3-in-1 advanced platform with deep cleansing, nourishment & hydration.
4) Alma Hybrid™, the first and only device to bring together 3 powerful energies - CO2 laser, 1570nm laser, ultrasound, to create a unique synergistic effect for skin rejuvenation and scar revision.



Note: the acquisition of foshion is still need to be approved by Annual General Meeting.

FOSUN PHARMA
Innovation for Good Health

Medical Devices – Respiratory and Professional Medical Device & Consumables

Respiratory Care

BREAS

Z1 portable continuous positive airway pressure (CPAP) machine:
The smallest, lightest, most portable cpap machine (259g)

iSleep home-used series non-invasive ventilator:
Integrate humidification and constant temperature function

Vivo series medical respiratory devices:
Multi-function respiratory devices, for home/hospital use

Professional Medical Device & Consumables

INTUITIVE FOSUN 直观复星

- At the end of 2020, **5,989** da Vinci surgical systems installed globally, including **3,720** in the US, **1,059** in Europe, **894** in Asia(225 quota in china), and **316** in the rest of the world; in the Asia-Pacific region, especially China, it is still in the early stage and has huge market potential;
- At the end of 2020, exclusive fieldof-use licenses for more than **4,000** U.S. and foreign patents.

CHINDEX

JIANYOUCHENGYE

Covering multiple professional devices including imaging equipment, ambulances and hair transplant robots, etc.

- EOS® Whole Body Bone 3D Modeling Imaging System

- BodyTom® portable full body CT systems

- ARTAS Hair Transplant Surgical Auxiliary Robot

- Negative Pressure Ambulances

FOSUN PHARMA
Innovation for Good Health

Medical Diagnosis

Medical Diagnosis

- Molecular Diagnosis
- Immuno-diagnosis
- Biochemical Diagnosis
- Microbiological Diagnosis
- POCT
- Mass Spectrometry Diagnosis

Broad diagnosis pipeline, innovative products and globalized commercial network

- In-house developed automatic luminescenece instrument and its matching reagent entered into the market and gradually increased the sales in 2020. The related reagent obtained the registration number.
- Mycare, an exclusive product for blood concentration monitoring of antipsychotic drugs, received recognition from end-users. The market expanded rapidly afterwards.
- Glycotest is under the registration phase.
- To tackle the COVID-19(2019-nCoV), in-house developed nucleic acid detection kits, which used fluorescence PCR method, obtained the emergency approval from the National Food and Drug Administration, achieved the Registraion Certificate for Medical Device (IVD). Numbers of test kits are qualified for American, European and Australian certifications.

FOSUN PHARMA
Innovation for Good Health

Contents



1 Financial Results

2 Pharmaceutical

3 Med Tech

4 Healthcare Service

5 Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Healthcare Services Segment Performance

Segment Revenue



Segment Results



Segment Profit



Pioneer in providing regional healthcare services with the help of the science and the internet

12 Specialty Departments: O.B., Cardiology, Neurology, Respiratory, Rehabilitation, Oncology, Orthopaedics, Clinical laboratory, Nursing, Nephrology, Pediatrics, Chinese Medicine

Integrate Fosun medical systems and provide high quality 24/7 offline and online doctor services

Pearl River Delta

- Expand healthcare services from Foshan Chancheng Hospital and Shenzhen Hengsheng Hospital; increase the regional impact

Yangtze River Delta

- Collaborate with hospitals affiliated with Fudan University and provide services over Shanghai, Zhejiang and southern part of Jiangsu

Cheng-Yu District

- Build the service chain based on Chongqing Xiongrong Aesthetic Hospital and expend gradually to other specialized services

FOSUN PHARMA
Innovation for Good Health

Contents



1 Financial Results

2 Pharmaceutical

3 Med Tech

4 Healthcare Service

5 Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Development Strategy

- Focus on the core field
- R&D is in compliance with the strategy
- Efficient capital investment and management
- Global collaboration

INnovation

INternationalization

- Solidify the industry status in China
- Build a globally-competitive pipeline
- Customized commercial team in the U.S., African, Indian and European markets
- Global supply chain management



INtelligentization

- Integrate different segments and platforms
- Enhance the efficiency and quality of R&D
- Upgrade manufacturing and quality monitoring system
- Increase marketing & sales capability in key platforms

INtegration

- Digital management capability improvement
- Digitalized R&D, manufacture and commercialization
- Resources and technologies to build smart hospital
- Ongoing digital innovation

FOSUN PHARMA
Innovation for Good Health

Strategic Planning of Segment Businesses

Pharma

R&D

- Through in-house R&D, co-development, in-license and incubation, focus on **oncology and immunology, four hypers (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, central nervous system** and other major therapeutic areas
- Build small molecule innovative drugs, antibody drugs, cell therapy platforms, actively explore cutting-edge technology fields such as RNA, oncolytic viruses and gene therapy

Manufacture

- Build **comprehensive formulation** manufacturing center, enhance **specialty formulation** manufacturing base, continue to expand production **capacity of biologic drugs.**
- Set Gland Pharma as front station to enhance manufacture system with **international standard**

Commercialization

- With the launch of innovative products, established the **innovative drug commercialization team**, the **new retail team**, the professional sales & marketing team in **Africa, Europe and the US**. A comprehensive support team is also constructed for **medical affairs**, **market access** and **brand promotion**.
- Continuously enhance the construction and integration of the commercialization system, adhering to the guidance of professional, branding and digital development.

Healthcare Service

- A total of **13** holding hospitals with **4,610** beds, covering **Pearl River Delta**, **Yangtze River Delta** and **Cheng-Yu District**, building the strategic network for both General Hospitals and Specialty Hospitals
- To develop the offline and online healthcare systems for health management
- Regional flagship hospitals include Foshan Chancheng and Shenzhen Hengsheng.

Medical Devices

- **Medical Aesthetic:** As the major medical aesthetic platform, sisram's business covers energy based medical aesthetic devices, professional dental devices and injectable, etc.
- **Respiratory Care:** Exploiting home/hospital used respiratory devices market through Breas
- **Professional Medical Device & Consumables:** Including Da Vinci surgical robotic system, negative pressure ambulances and other professional medical device with leading position in their own field

Medical diagnosis

- Fosun Long March and Yaneng Bio together cover **molecular diagnosis, immune diagnosis, biochemical diagnosis, microbiological diagnosis, POCT and mass spectrum diagnosis**

Note: the acquisition of foshion is still need to be approved by Annual General Meeting.

FOSUN PHARMA
Innovation for Good Health

Environmental, Social and Governance

- Environmental, Social and Governance (ESG) reflects a company's potential for sustainable growth in aspect of environmental protection, social responsibility and corporate governance.
- ESG became an increasingly import factor for evaluating a company's value while regulators issued higher requirements on ESG disclosure for listed companies.
- Fosun Pharma responded actively. In 2020, ESG Committee was established at Board Level.
- By the end of 2020 Fosun Pharma's MSCI ESG rating was improved **from BB to BBB**.

FOSUN PHARMA
Innovation for Good Health

Disclaimer and copyright

- 本文件中所包含的所有内容(包括预测性描述)，复星医药、陈述人或提供人不保证其完全准确、完整或及时，如因有关内容存在错误、遗漏或失准之处而引致的行为或结果，复星医药、陈述人或提供人对此不承担责任。
- 本文件内容不包含亦不应被视为任何投资建议，投资者基于本文件中内容做出的投资决策，责任自负。
- 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有，其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意，任何第三方不得以包括转载在内的任何方式加以使用。
- Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.
- The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.
- Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and”复星” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA
Innovation for Good Health

FOSUN PHARMA

复星医药

持续创新 · 乐享健康

复星医药微信公众平台

www.fosunpharma.com